TPCK Activators
TPCK Activators encompass a range of chemical compounds that indirectly augment TPCK's functional activity through diverse signaling pathways. Forskolin, by raising intracellular cAMP levels, indirectly enhances TPCK's function as the elevated cAMP activates PKA, leading to phosphorylation of proteins within TPCK's associated pathways. Similarly, Sildenafil, through PDE5 inhibition, increases cAMP and cGMP levels, indirectly boosting TPCK's activity via enhanced PKG activity. Genistein, as a tyrosine kinase inhibitor, lessens competitive signaling, allowing TPCK-associated pathways to be more active. LY294002 and Staurosporine modulate the PI3K/AKT and various kinase pathways, respectively. These modulations indirectly promote TPCK's activity by altering the cellular signaling equilibrium in favor of TPCK's pathways. Furthermore, U0126 and SB203580, by inhibiting MEK1/2 and p38 MAPK respectively, shift signaling dynamics to enhance TPCK's role, illustrating how TPCK's functional activity is intricately linked to these signaling pathways.
The impact of TPCK Activators extends with compounds like A23187 and Thapsigargin, which elevate intracellular calcium levels, thus activating calcium-dependent signaling pathways that intersect with TPCK's function. This enhancement underscores the sensitivity of TPCK activity to calcium signaling. Epigallocatechin gallate and Sphingosine-1-phosphate, through their respective kinase inhibition and receptor-mediated signaling, further contribute to the functional enhancement of TPCK by modulating the cellular signaling landscape. Lastly, PMA's role in activating PKC highlights the complexity of TPCK activation, as PKC activation can indirectly influence TPCK activity through interconnected signaling pathways. Collectively, these compounds, through their targeted effects on various cellular pathways, facilitate the enhancement of TPCK-mediated functions without the need for upregulating its expression or direct activation, showcasing the multifaceted nature of TPCK regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin raises intracellular cAMP levels, which can activate PKA. TPCK, being sensitive to changes in cAMP and PKA activity, gets functionally activated as PKA phosphorylates proteins involved in its associated pathways. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
As a tyrosine kinase inhibitor, Genistein reduces competitive signaling pathways, thereby allowing pathways involving TPCK to be more active and directly enhancing its functional role. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, modifies the PI3K/AKT pathway. This alteration can lead to a shift in cellular signaling balance, indirectly enhancing TPCK's functional activity through interconnected pathways. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, a broad-spectrum kinase inhibitor, may selectively activate TPCK pathways by inhibiting kinases that negatively regulate pathways associated with TPCK's function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, thus modulating the MAPK/ERK pathway. This inhibition can indirectly upregulate TPCK activity by shifting the signaling equilibrium towards TPCK-associated pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAPK, leading to the modulation of cellular responses in which TPCK is involved. This inhibition indirectly enhances TPCK's functional activity by affecting related signaling processes. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 increases intracellular calcium levels, which activates calcium-dependent signaling pathways. These pathways can interact with and enhance TPCK's functional role in the cell. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin elevates cytosolic calcium levels by inhibiting the SERCA pump, indirectly enhancing TPCK activity through calcium-mediated signaling pathways. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
As a kinase inhibitor, Epigallocatechin gallate can influence various signaling pathways, indirectly leading to the activation of TPCK by altering the cellular signaling landscape. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate acts on its receptors to modulate signaling pathways, potentially enhancing TPCK activity by influencing pathways that intersect with TPCK's functional role. | ||||||